Neurocrine Biosciences (NBIX)
Neurocrine Biosciences Profit Margin: -7.86%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NBIX Profit Margin Rankings
| Overall | 17th percentile | 3643 of 4397 |
| Sector | 42nd percentile | 271 of 470 in Healthcare |
| Industry | 69th percentile | 40 of 132 in Biotechnology |
NBIX Profit Margin Range, Past 5 Years
| Minimum | -54925% | Jun 2007 |
| Maximum | 75.38% | Sep 2011 |
| Average | -5119% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these NBIX related companies
NBIX News
Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
May 29, 1:00PM PR Newswire
May 29, 1:00PM PR Newswire
RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech
about 15 days ago by WolfsBiotechs
about 15 days ago by WolfsBiotechs
Neurocrine Biosciences' CEO Presents at Deutsche Bank 37th Annual Health Care Conference (Transcript)
May 09, 5:13PM Seeking Alpha
May 09, 5:13PM Seeking Alpha
Listen to $NBIX at deutsche bank ag health care conference - live at 11:20 AM, ondemand after - http://stks.co/3kDQ
about 22 days ago by earningscast
about 22 days ago by earningscast
Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Conference
May 04, 2:21PM PR Newswire
May 04, 2:21PM PR Newswire
Neurocrine Biosciences $NBIX in the MFI screen today. Small drug developer. Looks like a one-time revenue case, not certain though.
about 27 days ago by MagicDiligence
about 27 days ago by MagicDiligence
$NBIX 200 Day SMA Cross - Price crossed below 200 day SMA (7.2892). Confirmed by volume.
about 28 days ago by TradeIdeasQuant
about 28 days ago by TradeIdeasQuant
Neurocrine Biosciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript
May 02, 8:20PM Seeking Alpha
May 02, 8:20PM Seeking Alpha
Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
May 01, 11:00AM PR Newswire
May 01, 11:00AM PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
Apr 25, 4:20PM PR Newswire
Apr 25, 4:20PM PR Newswire
Jefferies Maintains a 'Buy' on Neurocrine (NBIX); Incrementally Encouraged on VMAT Program
Apr 04, 10:48AM Street Insider
Apr 04, 10:48AM Street Insider
Neurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conference
Mar 27, 4:05PM PR Newswire
Mar 27, 4:05PM PR Newswire
$NBIX is -5.5% down since open on unusual high volume and -11.9% down since close.
about 65 days ago by TradeBot
about 65 days ago by TradeBot
Jefferies Remains Positive on Neurocrine Bio. (NBIX) and NBI-98854 Despite Problems With Phase 2 Study Site
Mar 27, 8:23AM Street Insider
Mar 27, 8:23AM Street Insider
Neurocrine Biosciences (NBIX) Said Elagolix Endometriosis Phase III On Track After FDA Response to SPA
Mar 27, 8:10AM Street Insider
Mar 27, 8:10AM Street Insider
Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012
Mar 27, 8:02AM Benzinga
Mar 27, 8:02AM Benzinga
Neurocrine (NBIX) Shares Plunge as Data on NBI-98854 Fails to Hit Primary Endpoint
Mar 26, 4:08PM Street Insider
Mar 26, 4:08PM Street Insider
$NBIX Data From One Site Was Removed Due To The Inconsistent And Incorrect Application Of The Efficacy Assessment Protocol
about 66 days ago by Benzinga
about 66 days ago by Benzinga
Neurocrine (NBIX) Reports Notable Safety Results from NBI-98854 Phase II
Mar 26, 4:03PM Street Insider
Mar 26, 4:03PM Street Insider
Deutsche Bank Starts Neurocrine Bio. (NBIX) at Buy; Upside in 2012 as Investors Gain Confidence in Pipeline
Mar 15, 4:41PM Street Insider
Mar 15, 4:41PM Street Insider
IV30(TM) GAINER $NBIX +27.96% $AAPL +15.21% $BTU +10.73% $OSG +6.24%
about 77 days ago by livevol_pro
about 77 days ago by livevol_pro
Leerink Swann Starts Neurocrine Bio. (NBIX) at Outperform; Threading the Needle in Women's Health
Mar 08, 7:22AM Street Insider
Mar 08, 7:22AM Street Insider
Neurocrine Biosciences' CEO Citi 2012 Global Health Care Conference (Transcript)
Feb 29, 4:55PM Seeking Alpha
Feb 29, 4:55PM Seeking Alpha
Neurocrine Biosciences to Present at the 32nd Annual Cowen Health Care Conference
Feb 29, 2:00PM PR Newswire
Feb 29, 2:00PM PR Newswire
Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Feb 21, 4:50PM PR Newswire
Feb 21, 4:50PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NBIX | 6.45 | -0.08 | -1.23% | 427.25M |
| NBG | 1.44 | -0.08 | -5.26% | 1.377B |
| MOC | 1.10 | +0.01 | +0.92% | 11.81M |
| MOBI | 2.11 | -0.08 | -3.65% | 67.88M |
| MO | 32.02 | -0.11 | -0.34% | 65.50B |
| MNTG | 4.90 | +0.11 | +2.30% | 135.58M |
| MNTA | 13.83 | -0.14 | -1.00% | 709.89M |
| MNST | 73.64 | +0.60 | +0.82% | 12.84B |
| MNRO | 34.12 | -0.34 | -0.99% | 1.053B |
| MNRK | 9.95 | +0.00 | +0.00% | 59.10M |